CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04538352
NCT04538352Phase 4Completed
CompareCT.gov

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial

The Cleveland Clinic·interventional·Posted Sep 4, 2020·Updated Feb 18, 2025

In Brief

A Phase 4 clinical trial evaluating Semaglutide, Insulin Degludec, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsNovo Nordisk A/S

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedSep 4, 2020
Enrollment StartJan 18, 2021
Primary CompletionMar 31, 2023
Study CompletionNov 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.8 years ago

Interventions

Semaglutidedrug

Medication for type 2 diabetes management

Insulin Degludecdrug

Medication for type 2 diabetes management

Insulin aspartdrug

Medication for type 2 diabetes management (rapid-acting)